The first international collaboration focusing on the genetics of Alzheimer's disease has been announced by a group of multi-national researchers.
The four groups involved in the project are the European Alzheimer's Disease Initiative in France, the Alzheimer's Disease Genetics Consortium from the US, the Genetic and Environmental Risk in Alzheimer's Disease of the UK and the neurology subgroup of the Cohorts for Heart and Aging in Genomic Epidemiology.
Dr. Schellenberg, leader of the US group, said the research will "help lead us to the cause of the disease, identify proteins and other new targets for drug development, and provide genetic methods for determining which people are at greatest risk for Alzheimer's disease when preventative measures become available."
Meanwhile, research published in journal Human Molecular Genetics found that increasing brain peptidase puromycin-sensitive aminopeptidase can slow the progression of Alzheimer's disease.
Researchers found that increasing the peptidase in mammals slowed the accumulation of tau proteins that are toxic to nerve cells and lead to neurofibrillary tangles - a major characteristic of Alzheimer's.